Production (Stage)
Zenas BioPharma, Inc.
ZBIO
$11.43
-$0.02-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 100.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 100.00% | -- | |||
| Cost of Revenue | -28.97% | 46.61% | |||
| Gross Profit | 43.58% | -31.69% | |||
| SG&A Expenses | 8.28% | 53.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.93% | 47.92% | |||
| Operating Income | 32.89% | -35.72% | |||
| Income Before Tax | 35.26% | -35.15% | |||
| Income Tax Expenses | -147.79% | -- | |||
| Earnings from Continuing Operations | 36.18% | -36.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.18% | -36.26% | |||
| EBIT | 32.89% | -35.72% | |||
| EBITDA | 32.89% | -35.76% | |||
| EPS Basic | 35.97% | 74.99% | |||
| Normalized Basic EPS | 35.06% | 75.19% | |||
| EPS Diluted | 35.97% | 75.01% | |||
| Normalized Diluted EPS | 35.06% | 75.19% | |||
| Average Basic Shares Outstanding | -0.31% | 444.73% | |||
| Average Diluted Shares Outstanding | -0.31% | 444.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||